# Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/management-of-adverse-events-with-tailored-sorafenib-dosing-prolongs-survival-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Francesco Tovoli,Luca Ielasi,Andrea Casadei‐Gardini,Alessandro Granito,Francesco Giuseppe Foschi,Giulia Rovesti,Giulia Negrini,Giulia Orsi,Matteo Renzulli,Fabio Piscaglia |
| Citations | 84 |
| DOI | 10.1016/j.jhep.2019.08.015 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | http://hdl.handle.net/11380/1180466 |
| OpenAlex ID | https://openalex.org/W2969638445 |
| PMID | 31449860 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Giulia Orsi](https://scholariq.org/researchers/giulia-orsi/)

## Paper journal

- [Journal of Hepatology](https://scholariq.org/journals/journal-of-hepatology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.